Shattuck Labs, Inc. (STTK) Stock Price & Analysis

Shattuck Labs, Inc. (STTK) fell 2.65% to USD 6.61 as of September 8, 2026 at 14:10 UTC, according to Nexqual real-time market data.

STTK last closed at USD 6.61; the session ranged USD 6.49–6.86 on volume of 113,618 shares. Market capitalization is —, with a 52-week range of USD 1.68–8.33 (NMS). Source: Nexqual, September 8, 2026 at 14:10 UTC.

Key Statistics (as of September 8, 2026 at 14:10 UTC)

Technical Analysis (STTK)

Nexqual's technical model rates STTK "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 14:10 UTC.

From Shattuck Labs, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• Intellectual Property We strive to protect and enhance our proprietary technology, inventions, and improvements that we consider commercially important to the development of our business, including by seeking, maintaining, and defending U.S. and foreign patent rights, including patents covering our platform technologies, product candidates, and methods of using the same, whether developed internally or licensed from third parties.
• This agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.
• We also rely on trade secrets, know-how, and continuing technological innovation to develop, strengthen and maintain our proprietary position in our field.

Partnerships

• Because DR3 is a membrane-restricted target, immune complex formation is not expected either for SL-325, SL-425, or DR3 directed bispecific antibodies. 7 Manufacturing and Supply By working with third-party vendors to conduct activities in compliance with current Good Manufacturing Practices ("cGMP"), we have invested significant resources to identify and scale up a suitable manufacturing process for our product candidates, including SL-325.
• We manufacture bulk drug substance ("BDS") for SL-325 utilizing the services of a single third-party contract manufacturer, Kemwell Biopharma Private Limited ("Kemwell"), with whom we maintain a master service agreement, pursuant to which Kemwell manufactures BDS on a per project basis.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 14:10 UTC. This page is informational and not investment advice.